Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients

International Journal of Cancer

Volumn 129, Issue 2, 2011, Pages 507-512

  Desar, Ingrid M E ^a   Jacobs, J F M ^a   Hulsbergen VandeKaa, Christina A ^a   Oyen, Wim J G ^a   Mulders, Peter F A ^a   Van Der Graaf, Winette T A ^a   Adema, Gosse J ^a   Van Herpen, Carla M L ^a   De Vries, I J M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Immunotherapy; Regulatory T cell; Renal cell carcinoma; Sorafenib; Tyrosine kinase inhibitor

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; SORAFENIB; TRANSCRIPTION FACTOR FOXP3; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ARTICLE; ASCITES TUMOR; BIOACCUMULATION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; ADJUVANT THERAPY; IMMUNOLOGY; KIDNEY TUMOR; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOADJUVANT THERAPY; PROTEIN KINASE INHIBITORS; PYRIDINES; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 79961125367     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25674     Document Type: Article

References (25)

1. Bromwich EJ, McArdle PA, Canna K, McMillan DC, McNicol AM, Brown M, Aitchison M. The relationship between Tlymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 2003;89: 1906-8. (Pubitemid 37533268)
2. Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, et al. Tumorinfiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007;13: 2075-81. (Pubitemid 46649875)
3. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119-32.
4. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117: 1167-74. (Pubitemid 46718401)
5. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18-32. (Pubitemid 33070205)
6. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115: 3623-33. (Pubitemid 43121851)
7. Griffiths RW, Elkord E, Gilham DE, Ramani V, Clarke N, Stern PL, Hawkins RE. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007;56: 1743-53. (Pubitemid 47313079)
8. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R, Bukowski R. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82.
9. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15: 2148-57.
10. Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, Weinschenk T, Singh-Jasuja H, Brossart P. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008;111: 5610-20.
11. Molhoek KR, McSkimming CC, Olson WC, Brautigan DL, Slingluff CL, Jr. Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunol Immunother 2009;58: 867-76.
12. Jacobs JF, Idema AJ, Bol KF, Nierkens S, Grauer OM, Wesseling P, Grotenhuis JA, Hoogerbrugge PM, de V, I, Adema GJ. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol 2009;11:394-402.
13. Belkaid Y, Oldenhove G. Tuning microenvironments: Induction of regulatory T cells by dendritic cells. Immunity 2008; 29:362-71.
14. Darrasse-Jeze G, Deroubaix S, Mouquet H, Victora GD, Eisenreich T, Yao KH, Masilamani RF, Dustin ML, Rudensky A, Liu K, Nussenzweig MC. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med 2009;206: 1853-62.
15. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007;204: 1765-74. (Pubitemid 47236315)
16. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9. (Pubitemid 39273735)
17. Wei S, Kryczek I, Zou W. Regulatory Tcell compartmentalization and trafficking. Blood 2006;108:426-31.
18. Gobert M, Treilleux I, driss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, Perez S, Pasqual N, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009;69:2000-9.
19. Jacobs JF, Idema AJ, Bol KF, Grotenhuis JA, de V, I, Wesseling P, Adema GJ. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol 2010;225:195-199.
20. Ribatti D, Crivellato E. Immune cells and angiogenesis. J Cell Mol Med 2009;13: 2822-33
21. Croci DO, Zacarias Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 2007;56:1687-700. (Pubitemid 47313090)
22. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, Schwartz M, Divino CM, Pan PY, Chen SH. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immunebased cancer therapies. Cancer Res 2009;69: 2514-22.
23. Ruter J, Barnett BG, Kryczek I, Brumlik MJ, Daniel BJ, Coukos G, Zou W, Curiel TJ. Altering regulatory T cell function in cancer immunotherapy: A novel means to boost the efficacy of cancer vaccines. Front Biosci 2009;14:1761-70.
24. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of selftolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64.
25. Bacha P, Williams DP, Waters C, Williams JM, Murphy JR, Strom TB. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med 1988;167: 612-22. (Pubitemid 18073658)